Page 88 - Read Online

43. Vinik A, Wolin EM, Audry H, Gomez-Panzani EL; ELECT Study J, Li Y, Shen L. Feasibility and efficacy of combined cisplatin plus
Group. ELECT: A phase 3 study of efficacy and safety of lanreotide irinotecan chemotherapy for gastroenteropancreatic neuroendocrine
aurogel/depot (LAN) treatment for carcinoid syndrome in patients carcinomas. Med Oncol 2013;30:664.
with neuroendocrine tumors (NETs) (abstract). ASCO Meeting 60. Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J,
Abstracts 2014;32:268. Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere
44. Caplin ME, Pavel M, Cwikla JB, Phan AT, Sedlackova E, Cadio G, T, Caramella C, Schlumberger M, Planchard D, Elias D, Ducreux M,
Wolin EM, Capdevilla J, Wall L, Rindi G, Langley A, Martinez S, Scoazec JY, Baudin E. Are G3 ENETS neuroendocrine neoplasms
Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide heterogeneous? Endocr Relat Cancer 2013;20:649-57.
in metastatic enteropancreatic neuroendocrine tumors. N Engl J 61. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo
Med 2014;371:224-33. G, Barriuso J, Pavel M, O’Toole D, Walter T; other Knowledge
45. Bruns C, Lewis I, Briner U, Briner U, Meno-Tetang G, Weckbecker Network members. Characteristics and treatment of patients with
G. SOM-230: a novel somatostatin peptidomimetic with broad G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr
somatotropin release inhibiting factor (SRIF) receptor binding and Relat Cancer 2015;22:657-64.
a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16. 62. Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo
46. Schimd HA. Pasireotide (SOM230): development, mechanism M, Maire F, Goujon G, Gillet A, Lévy P, Ruszniewski P. FOLFIRI
of action and potential applications. Mol Cell Endocrinol regimen: an effective second-line chemotherapy after failure of
2008;286:69-74. etoposide-platinum combination in patients with neuroendocrine
47. Ben-Shlomo A, Melmed S. Pasireotide -- a somatostatin analog for carcinomas grade 3. Endocr Relat Cancer 2012;19:751-7.
the potential treatment of acromegaly, neurendocrine tumors and 63. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg
Cushing’s disease. IDrugs 2007;10:885-95. K. Clinical effect of temozolomide- based chemotherapy in poorly
48. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. differentiated endocrine carcinoma after progression on first-line
Current status of gastrointestinal carcinoids. Gastroenterology chemotherapy. Cancer 2011;117:4617-22.
2005;128:1717-51. 64. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao
49. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla JC. Fluorouracil, doxorubicin, and streptozotocin in the treatment of
EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred patients with locally advanced and metastatic pancreatic endocrine
years after ‘carcinoid’: epidemiology of and prognostic factors for carcinomas. J Clin Oncol 2004;22:4762-71.
neuroendocrine tumors in 35,825 cases in the United States. J Clin 65. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di
Oncol 2008;26:3063-72. Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L.
50. Lepage C, Rachet B, Coleman MP. Survival from malignant 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of
digestive endocrine tumors in England and Wales: a population- patients with neuroendocrine tumors. Cancer 1998;83:372-8.
based study. Gastroenterology 2007;132:899-904. 66. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT,
51. Pape UF, Berndt U, Mueller-Nordhorn J, Müller-Nordhorn Helm J, Kvols L. First-line chemotherapy with capecitabine and
J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B. temozolomide in patients with metastatic pancreatic endocrine
Prognostic factors of long-term outcome in gastroenteropancreatic carcinomas. Cancer 2011;117:268-75.
neuroendocrine tumours. Endocr Relat Cancer 2008;15:1083-97. 67. Cassier PA, Walter T, Bohas CL, Ardisson P, Perol M, Paillet C,
52. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Chayvialle JA, Scoazec JY, Hervieu V, Bohas CL. Gemcitabine
Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, and oxaliplatin combination chemotherapy for metastatic well-
Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin differentiated neuroendocrine carcinomas. Cancer 2009;115: 3392-9.
A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 68. Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci
2008;9:61-72. S, Di Costanzo F, Fontana A, Gelsomino F, Luppi G, Nobili E, Galdy
53. Bosman FT, Carneiro F, Hruban RH, Thiese N, editors. World Health S, Cella CA, Sonzogni A, Pisa E, Barberis M, Fazio N. Oxaliplatin-
Organization Classification of Tumours. Pathology and Genetics. based chemotherapy in advanced neuroendocrine tumors: clinical
Tumors of the Digestive System. Lyon: IARC Press, 2010. outcomes and preliminary correlation with biological factors.
54. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Neuroendocrinology 2016 Jan 21; doi:10.1159/000444087.
Pathology and genetics of tumors of the lung, pleura, thymus and 69. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione
heart. Geneva: IARC Press, 2004. F, Birocco N, Bombaci S, Perroni D, Ferretti B, Alabiso O, Ciuffreda
55. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of L, Bertetto O, Papotti M, Dogliotti L. Continuous 5-fluorouracil
neuroendocrine carcinomas with combined etoposide and cisplatin. infusion plus long acting octreotide in advanced well-differentiated
Evidence of major therapeutic activity in the anaplastic variants of neuroendocrine carcinomas. A phase II trial of the Piemonte
these neoplasms. Cancer 1991;68:227-32. oncology network. BMC Cancer 2009;9:388.
56. Mitry E, Baudin E, Ducreaux M, Sabourin JC, Rufié P, Aparicio T, 70. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti
Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier A, Dogliotti L, Scagliotti GV, Papotti M. Thymidylate synthase
P. Treatment of poorly differentiated neuroendocrine tumours with expression in gastroenteropancreatic and pulmonary neuroendocrine
etoposide and cisplatin. Br J Cancer 1999;81:1351-5. tumors. Clin Cancer Res 2008;14:1059-64.
57. Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, 71. Lim E, Goldstraw P, Nicholson G, Travis WD, Jett JR, Ferolla
Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in P, Bomaji J, Rusch VW, Asamura H, Skogseid B, Baudin EE,
patients with neuroendocrine tumors. Cancer 2001; 92:1101-7. Caplin M, Kwekkeboom D, Brambilla E, Crowley J. Proceedings
58. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, of the IASLC International Workshop on Advances in Pulmonary
Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka Neuroendocrine Tumors 2007. J Thorac Oncol 2008;3:1194-201.
N. Cisplatin and etoposide as first-line chemotherapy for poorly 72. Crona J, Björklund P, Welin S, Kozlovacki G, Öberg K, Granberg
differentiated neuroendocrine carcinoma of the hepatobiliary tract D. Treatment, prognostic markers and survival in thymic
and pancreas. Jpn J Clin Oncol 2010;40:313-8. neuroendocrine tumours. A study from a single tertiary referral
59. Lu ZH, Li J, Lu N, Zhang XT, Li J, Zhou J, Wang XC, Gong JF, Gao centre. Lung Cancer 2013;79:289-93.

320
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦